Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Orizuru Therapeutics Inc. currently manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 3 distinct examiners and 2 distinct art units. GU, QINHUA is the busiest examiner for the portfolio, with 1 pending case.
This distribution shows that the company's active prosecution is spread across multiple officials while being concentrated in a small number of art units. The company must navigate different examiner styles within the biotech sector. Practitioners should monitor the 2 distinct art units to identify any conflicting requirements that might arise during prosecution.
Since the busiest examiner only handles a single case, the firm's strategy is not overly reliant on any one individual's interpretation. This approach allows for a broader range of examiner interactions, which can help the company refine its overall filing strategy as it navigates the complex biotech sector. By engaging with multiple examiners, the company can gain diverse perspectives on claim patentability, potentially leading to a more robust portfolio.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GU, QINHUA | 1 | 75.9% | +27.8% |
| TRAN, KHOA NHAT | 1 | 43.2% | +53.3% |
| DHAR, MATASHA | 1 | 43.3% | +45.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17277406 | INSULIN-PRODUCING CELLS | TRAN, KHOA NHAT | 113d overdue |
| 17049218 | GROWTH INHIBITOR | DHAR, MATASHA | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17277406 | INSULIN-PRODUCING CELLS | TRAN, KHOA NHAT | 113d overdue |
| 17049218 | GROWTH INHIBITOR | DHAR, MATASHA | 23d overdue |
| 18273441 | MATURATION AGENT | GU, QINHUA | 33d |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18273441 | MATURATION AGENT | GU, QINHUA | 1633 | §103 | Final Rejection | 33d | Pending | Jul 20, 2023 |
| 17277406 | INSULIN-PRODUCING CELLS | TRAN, KHOA NHAT | 1632 | §101§103§112 | Non-Final OA | 113d overdue | Pending | Mar 18, 2021 |
| 17049218 | GROWTH INHIBITOR | DHAR, MATASHA | 1632 | §102§103 | Non-Final OA | 23d overdue | Pending | Oct 20, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial